Stifel upgraded Denali Therapeutics (DNLI) to Buy from Hold with a $37 price target Denali recently aligned with the FDA to file for accelerated approval for their lead candidate DLN310/tividenofusp alfa in MPS IIA/Hunter syndrome with a BLA submission expected early-2025, which “represents a major win,” the analyst tells investors. Though the firm thinks DNL310 should get approved, there are “still a number of outstanding questions,” the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics announces first patient dosed in Phase 2a study of BIIB122
- Denali Therapeutics management to meet with B. Riley
- Denali Therapeutics Advances Brain Disease Therapies
- Denali Therapeutics sees Fy24 opex increase of 5%-10% year-over-year
- Denali Therapeutics reports Q3 EPS (63c), consensus (61c)